10 Facts About Agomelatine


Agomelatine, sold under the brand names Valdoxan and Thymanax, among others, is an atypical antidepressant most commonly used to treat major depressive disorder.

FactSnippet No. 626,650

Agomelatine was approved for medical use in Europe in 2009 and Australia in 2010.

FactSnippet No. 626,651

Agomelatine is used for the treatment of major depressive episodes in adults in Europe.

FactSnippet No. 626,652

Agomelatine has been found more effective than placebo in the treatment of generalized anxiety disorder in a number of short-term double-blind placebo-controlled studies and in long term relapse prevention.

FactSnippet No. 626,653

Agomelatine is contraindicated in patients with kidney or liver impairment.

FactSnippet No. 626,654

Related searches

Australia Europe

Agomelatine induced an advance of the time of sleep onset and of minimum heart rate.

FactSnippet No. 626,655

Agomelatine has no abuse potential as measured in healthy volunteer studies.

FactSnippet No. 626,656

Agomelatine has shown an antidepressant-like effect in animal models of depression as well as in models with circadian rhythm desynchronisation and in models related to stress and anxiety.

FactSnippet No. 626,657

Agomelatine was discovered and developed by the European pharmaceutical company Servier Laboratories Ltd.

FactSnippet No. 626,658

Agomelatine has been investigated for its effects on sleep regulation due its actions as a melatonin receptor agonist.

FactSnippet No. 626,659